Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx – ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Explore the evolving RVO treatment landscape from anti-VEGF breakthroughs to pipeline innovations addressing unmet needs in efficacy, safety, and dosing burden. Retinal Vein Occlusion care is entering ...

A new partnership between Oceanside Unified and MiraCosta College will offer students the opportunity to earn a ...

California says the sale of 23andMe to a nonprofit formed by the company's former CEO would skirt a state law specifically ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Jun 16, 2025-- ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein ...